Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies

Autoimmunity Reviews

Volumn 13, Issue 3, 2014, Pages 225-230

  Shi, Jing ^a   van Veelen, Peter A ^a   Mahler, Michael ^b   Janssen, George M C ^a   Drijfhout, Jan W ^a   Huizinga, Tom W J ^a   Toes, Rene E M ^a   Trouw, Leendert A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

Anti carbamylated protein antibodies; Carbamylation; Cardiovascular diseases; Cataract; Chronic kidney diseases; Rheumatoid arthritis

Indexed keywords

AMINE; CARBAMOYLTRANSFERASE; CARBAMYLATED PROTEIN ANTIBODY; CYANIC ACID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HOMOCITRULLINE; LYSINE; LYSINE CARBAMYLTRANSFERASE; PROTEIN ANTIBODY; THIOL GROUP; UNCLASSIFIED DRUG; UREA;

ARTHRALGIA; AUTOIMMUNITY; CARBAMOYLATION; CARDIOVASCULAR DISEASE; CATARACT; CELL FUNCTION; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; INHALATION; KIDNEY DISEASE; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; UREA BLOOD LEVEL;

ANTI-CARBAMYLATED PROTEIN ANTIBODIES; CARBAMYLATION; CARDIOVASCULAR DISEASES; CATARACT; CHRONIC KIDNEY DISEASES; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES; AUTOIMMUNITY; CARBAMATES; HUMANS; INFLAMMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS;

EID: 84891747527     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.10.008     Document Type: Review

References (109)

1. Schreier S.M., Steinkellner H., Jirovetz L., Hermann M., Exner M., Gmeiner B.M., et al. S-carbamoylation impairs the oxidant scavenging activity of cysteine: its possible impact on increased LDL modification in uraemia. Biochimie 2011, 93:772-777.
2. Gross M.L., Piecha G., Bierhaus A., Hanke W., Henle T., Schirmacher P., et al. Glycated and carbamylated albumin are more "nephrotoxic" than unmodified albumin in the amphibian kidney. Am J Physiol Renal Physiol 2011, 301:F476-F485.
3. Hagel P., Gerding J.J.T., Fieggen W., Bloemendal H. Cyanate formation in solutions of urea: I. calculation of cyanate concentrations at different temperature and pH. Biochim Biophys Acta 1971, 243:366-373.
4. Trepanier D.J., Thibert R.J. Carbamylation of erythrocyte membrane aminophospholipids: an in vitro and in vivo study. Clin Biochem 1996, 29:333-345.
5. Lapko V.N., Smith D.L., Smith J.B. Methylation and carbamylation of human gamma-crystallins. Protein Sci 2003, 12:1762-1774.
6. Fluckiger R., Harmon W., Meier W., Loo S., Gabbay K.H. Hemoglobin carbamylation in uremia. N Engl J Med 1981, 304:823-827.
7. Erill S., Calvo R., Carlos R. Plasma-protein carbamylation and decreased acidic drug protein-binding in uremia. Clin Pharmacol Ther 1980, 27:612-618.
8. Kraus L.M., Kraus A.P. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001, 59:S102-S107.
9. Wang Z., Nicholls S.J., Rodriguez E.R., Kummu O., Horkko S., Barnard J., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007, 13:1176-1184.
10. Holzer M., Zangger K., El-Gamal D., Binder V., Curcic S., Konya V., et al. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. Antioxid Redox Signal 2012, 17:1043-1052.
11. Klebanoff S.J. Myeloperoxidase: friend and foe. J Leukoc Biol 2005, 77:598-625.
12. Kalmar J., Woldegiorgis K.L., Biri B., Ashby M.T. Mechanism of decomposition of the human defense factor hypothiocyanite near physiological pH. J Am Chem Soc 2011, 133:19911-19921.
13. Prokopowicz Z., Marcinkiewicz J., Katz D.R., Chain B.M. Neutrophil myeloperoxidase: soldier and statesman. Arch Immunol Ther Exp (Warsz) 2012, 60:43-54.
14. Roberts J.M., Veres P.R., Cochran A.K., Warneke C., Burling I.R., Yokelson R.J., et al. Isocyanic acid in the atmosphere and its possible link to smoke-related health effects. Proc Natl Acad Sci U S A 2011, 108:8966-8971.
15. Mun K.C., Kim H.C., Kwak C.S. Cyanate as a hemolytic factor. Ren Fail 2000, 22:809-814.
16. Qian M., Eaton J.W., Wolff S.P. Cyanate-mediated inhibition of neutrophil myeloperoxidase activity. Biochem J 1997, 326:159-166.
17. Ha E. Cyanate attenuates insulin secretion in cultured pancreatic beta cells. Mol Med Rep 2012, 5:1461-1464.
18. Hommes F.A., Eller A.G., Scott D.F., Carter A.L. Separation of ornithine and lysine activities of the ornithine-transcarbamylase-catalyzed reaction. Enzyme 1983, 29:271-277.
19. Carter A.L., Eller A.G., Rufo S., Metoki K., Hommes F.A. Further evidence for a separate enzymic entity for the synthesis of homocitrulline, distinct from the regular ornithine transcarbamylase. Enzyme 1984, 32:26-36.
20. Crist R.D., Grisolia S., Bettis C.J., Grisolia J. Carbamoylation of proteins following administration to rats of carbamoyl phosphate and cyanate and effects on memory. Eur J Biochem 1973, 32:109-116.
21. Roxborough H.E., Millar C.A., Mceneny J., Young I.S. Carbamylation inhibits the ferroxidase activity of ceruloplasmin. Biochem Biophys Res Commun 1995, 214:1073-1078.
22. Jung K., Mildner D., Jacob B., Scholz D., Precht K. On the pyridoxal-5'-phosphate stimulation of aspartate aminotransferase and alanine aminotransferase in serum and erythrocytes of patients undergoing chronic haemodialysis and with kidney transplants. Clin Chim Acta 1981, 115:105-110.
23. Oimomi M., Hatanaka H., Yoshimura Y., Yokono K., Baba S., Taketomi Y. Carbamylation of insulin and its biological-activity. Nephron 1987, 46:63-66.
24. Mun K.C., Golper T.A. Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purif 2000, 18:13-17.
25. Ramirez R., Carracedo J., Nogueras S., Buendia P., Merino A., Canadillas S., et al. Carbamylated darbepoetin derivative prevents endothelial progenitor cell damage with no effect on angiogenesis. J Mol Cell Cardiol 2009, 47:781-788.
26. Coleman T.R., Westenfelder C., Togel F.E., Yang Y., Hu Z., Swenson L., et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A 2006, 103:5965-5970.
27. Williams R.C., Kim H. Carbamoylated hemoglobins A and S: physical properties. Biochemistry 1976, 15:2207-2211.
28. Cerami A., Allen T.A., Graziano J.H., Defuria F.G., Manning J.M., Gillette P.N. Pharmacology of cyanate. I. General effects on experimental-animals. J Pharmacol Exp Ther 1973, 185:653-666.
29. Alter B.P., Kan Y.W., Nathan D.G. Toxic effects of high-dose cyanate administration in rodents. Blood 1974, 43:69-77.
30. Dengler T.J., Rohertz-Vaupel G.M., Dengler H.J. Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 1992, 43:491-499.
31. Jaisson S., Lorimier S., Ricard-Blum S., Sockalingum G.D., Delevallee-Forte C., Kegelaer G., et al. Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem Biol 2006, 13:149-159.
32. Kuckel C.L., Lubit B.W., Lambooy P.K., Farnsworth P.N. Methylisocyanate and actin polymerization - the in vitro effects of carbamylation. Biochim Biophys Acta 1993, 1162:143-148.
33. Mellado W., Slebe J.C., Maccioni R.B. Tubulin carbamoylation - functional amino-groups in microtubule assembly. Biochem J 1982, 203:675-681.
34. Jaisson S., Larreta-Garde V., Bellon G., Hornebeck W., Garnotel R., Gillery P. Carbamylation differentially alters type I collagen sensitivity to various collagenases. Matrix Biol 2007, 26:190-196.
35. Hood W., Morena E.D.L., Grisolia S. Increased susceptibility of carbamylated glutamate-dehydrogenase to proteolysis. Acta Biol Med Ger 1977, 36:1667-1672.
36. Springer G.F., Yang H.J., Desai P.R., Jirgensons B. Effect of carbamylation of lysine epsilon-amino groups on activity of blood-group specific glycoproteins. Immunol Commun 1975, 4:553-564.
37. Schreier S.M., Hollaus M., Hermann M., Jirovetz L., Exner M., Kapiotis S., et al. Carbamoylated free amino acids in uremia: HOCl generates volatile protein modifying and cytotoxic oxidant species from N-carbamoyl-threonine but not threonine. Biochimie 2012, 94:2441-2447.
38. Kraus L.M., Jones M.R., Kraus A.P. Essential carbamoyl-amino acids formed in vivo in patients with end-stage renal disease managed by continuous ambulatory peritoneal dialysis: isolation, identification, and quantitation. J Lab Clin Med 1998, 131:425-431.
39. Lane T.A., Burka E.R. Decreased life-span and membrane damage of carbamylated erythrocytes in vitro. Blood 1976, 47:909-917.
40. Cammer W. Release of mitochondrial respiratory control by cyanate salts. Biochim Biophys Acta 1982, 679:343-346.
41. Jaisson S., Delevallee-Forte C., Toure F., Ieu P., Garnotel R., Gillery P. Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst. FEBS Lett 2007, 581:1509-1513.
42. Shaykh M., Pegoraro A.A., Mo W., Arruda J.A.L., Dunea G., Singh A.K. Carbamylated proteins activate glomerular mesangial cells and stimulate collagen deposition. J Lab Clin Med 1999, 302-308.
43. Lee H.S. Oxidized LDL, glomerular mesangial cells and collagen. Diabetes Res Clin Pract 1999, 45:117-122.
44. Ha E., Bang J.H., Son J.N., Cho H.C., Mun K.C. Carbamylated albumin stimulates microRNA-146, which is increased in human renal cell carcinoma. Mol Med Rep 2010, 3:275-279.
45. Garnotel R., Sabbah N., Jaisson S.P., Gillery P. Enhanced activation of and increased production of matrix metalloproteinase-9 by human blood monocytes upon adhering to carbamylated collagen. FEBS Lett 2004, 563:13-16.
46. Chang H., Ewert S.M., Bookchin R.M., Nagel R.L. Comparative evaluation of fifteen anti-sickling agents. Blood 1983, 61:693-704.
47. Cerami A. Review of the development of cyanate as a drug in the treatment of sickle cell anemia. Ann N Y Acad Sci 1974, 241:538-544.
48. Peterson C.M., Tsairis P.E.T.E., Ohnishi A.K.I.O., Lu Y.S., Grady R.O.B.E., Cerami A.N.T.H., et al. Sodium cyanate induced polyneuropathy in patients with sickle-cell disease. Ann Intern Med 1974, 81:152-158.
49. Shaw C.M., Papayannopoulou T., Stamatoyannopoulos G. Neuropathology of cyanate toxicity in rhesus monkeys. Pharmacology 1974, 12:166-176.
50. Kogure K., Busto R., Cassel J., Kim C.Y., Harkness D.R. Effects of high-dose cyanate upon cerebral energy metabolism of rat. Pharmacology 1975, 13:391-400.
51. Tor-Agbidye J., Palmer V.S., Spencer P.S., Craig A.M., Blythe L.L., Sabri M.I. Sodium cyanate alters glutathione homeostasis in rodent brain: relationship to neurodegenerative diseases in protein-deficient malnourished populations in Africa. Brain Res 1999, 820:12-19.
52. Sokolowska M., Lorenc-Koci E., Bilska A., Iciek M.G. The effect of lipoic acid on cyanate toxicity in different structures of the rat brain. Neurotox Res 2013, 24:345-357.
53. Sokolowska M., Niedzielska E., Iciek M., Bilska A., Lorenc-Koci E., Wlodek L. The effect of the uremic toxin cyanate (CNO-) on anaerobic cysteine metabolism and oxidative processes in the rat liver: a protective effect of lipoate. Toxicol Mech Methods 2011, 21:473-478.
54. Kraus L.M., Kraus A.P. Tyrosine and N-carbamoyl-tyrosine in end-stage renal-disease during continuous ambulatory peritoneal-dialysis. J Lab Clin Med 1991, 118:555-562.
55. Kwan J.T.C., Carr E.C., Neal A.D., Burdon J., Raftery M.J., Marsh F.P., et al. Carbamylated haemoglobin, urea kinetic modelling and adequacy of dialysis in haemodialysis patients. Nephrol Dial Transplant 1991, 6:38-43.
56. Smith W.G.J., Holden M., Benton M., Brown C.B. Carbamylated haemoglobin in chronic renal failure. Clin Chim Acta 1988, 178:297-303.
57. Tang W., Shrestha K., Wang Z., Borowski A.G., Troughton R.W., Klein A.L., et al. Protein carbamylation in chronic systolic heart failure: relationship with renal impairment and adverse long-term outcomes. J Card Fail 2013, 19:219-224.
58. Koeth R.A., Kalantar-Zadeh K., Wang Z., Fu X., Tang W., Hazen S.L. Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol 2013, 24:853-861.
59. Berg A.H., Drechsler C., Wenger J., Buccafusca R., Hod T., Kalim S., et al. Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 2013, 5:175ra29.
60. Nicholson D.H., Harkness D.R., Benson W.E., Peterson C.M. Cyanate-induced cataracts in patients with sickle-cell hemoglobinopathies. Arch Ophthalmol 1976, 94:927-930.
61. Kern H.L., Bellhorn R.W., Peterson C.M. Sodium cyanate-induced ocular lesions in beagle. J Pharmacol Exp Ther 1977, 200:10-16.
62. Lapko V.N., Smith D.L., Smith J.B. In vivo carbamylation and acetylation of water-soluble human lens alpha B-crystallin lysine 92. Protein Sci 2001, 10:1130-1136.
63. Beswick H.T., Harding J.J. High-molecular-weight crystallin aggregate formation resulting from nonenzymatic carbamylation of lens crystallins - relevance to cataract formation. Exp Eye Res 1987, 45:569-578.
64. Beswick H.T., Harding J.J. Conformational-changes induced in bovine lens alpha-crystallin by carbamylation - relevance to cataract. Biochem J 1984, 223:221-227.
65. Holzer M., Gauster M., Pfeifer T., Wadsack C., Fauler G., Stiegler P., et al. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 2011, 14:2337-2346.
66. Apostolov E.O., Ray D., Savenka A.V., Shah S.V., Basnakian A.G. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 2010, 21:1852-1857.
67. Rajkovic M.G., Rumora L., Barisic K. The paraoxonase 1, 2 and 3 in humans. Biochem Med (Zagreb) 2011, 21:122-130.
68. Kunnen S., Van Eck M. Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?. J Lipid Res 2012, 53:1783-1799.
69. Apostolov E.O., Basnakian A.G., Yin X., Ok E., Shah S.V. Modified LDLs induce proliferation-mediated death of human vascular endothelial cells through MAPK pathway. Am J Physiol Heart Circ Physiol 2007, 292:H1836-H1846.
70. Son J.N., Lho Y., Shin S., Kwon S.H., Moon K.C., Ha E. Carbamylated low-density lipoprotein increases reactive oxygen species (ROS) and apoptosis via lectin-like oxidized LDL receptor (LOX-1) mediated pathway in human umbilical vein endothelial cells. Int J Cardiol 2011, 146:428-430.
71. Ok E., Basnakian A.G., Apostolov E.O., Barri Y.M., Shah S.V. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005, 68:173-178.
72. Apostolov E.O., Ray D., Alobuia W.M., Mikhailova M.V., Wang X., Basnakian A.G., et al. Endonuclease G mediates endothelial cell death induced by carbamylated LDL. Am J Physiol Heart Circ Physiol 2011, 300:H1997-H2004.
73. Apostolov E.O., Shah S.V., Ray D., Basnakian A.G. Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL. Arterioscler Thromb Vasc Biol 2009, 29:1622-1630.
74. Gonen B., Cole T., Hahm K.S. The interaction of carbamylated low-density lipoprotein with cultured-cells - studies with human-fibroblasts, rat peritoneal-macrophages and human monocyte-derived macrophages. Biochim Biophys Acta 1983, 754:201-207.
75. Apostolov E.O., Shah S.V., Ok E., Basnakian A.G. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2007, 27:826-832.
76. Carracedo J., Merino A., Briceno C., Soriano S., Buendia P., Calleros L., et al. Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J 2011, 25:1314-1322.
77. Asci G., Basci A., Shah S.V., Basnakian A., Toz H., Ozkahya M., et al. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells. Nephrology (Carlton) 2008, 13:480-486.
78. El-Gamal D., Holzer M., Gauster M., Schicho R., Binder V., Konya V., et al. Cyanate is a novel inducer of endothelial ICAM-1 expression. Antioxid Redox Signal 2012, 16:129-137.
79. Horkko S., Savolainen M.J., Kervinen K., Kesaniemi Y.A. Carbamylation-induced alterations in low-density lipoprotein metabolism. Kidney Int 1992, 41:1175-1181.
80. Horkko S., Huttunen K., Kervinen K., Kesaniemi Y.A. Decreased clearance of uremic and mildly carbamylated low-density-lipoprotein. Eur J Clin Invest 1994, 24:105-113.
81. Willemze A., Trouw L.A., Toes R.E.M., Huizinga T.W.J. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012, 8:144-152.
82. Ahmad J., Gupta A., Alam K., Farooqui K.J. Detection of autoantibodies against glycosylated-DNA in diabetic subjects: its possible correlation with HbA(1C). Dis Markers 2011, 30:235-243.
83. Wu J.T., Wu L.L. Autoantibodies against oxidized LDL - a potential marker for atherosclerosis. Clin Lab Med 1997, 17:595-604.
84. Steinbrecher U.P., Fisher M., Witztum J.L., Curtiss L.K. Immunogenicity of homologous low-density lipoprotein after methylation, ethylation, acetylation, or carbamylation - generation of antibodies specific for derivatized lysine. J Lipid Res 1984, 25:1109-1116.
85. Mydel P., Wang Z., Brisslert M., Hellvard A., Dahlberg L.E., Hazen S.L., et al. Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol 2010, 184:6882-6890.
86. Shi J., Knevel R., Suwannalai P., van der Linden M.P., Janssen G.M.C., van Veelen P.A., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011, 108:17372-17377.
87. Kummu O., Turunen S.P., Wang C., Lehtimaki J., Veneskoski M., Kastarinen H., et al. Carbamyl adducts on low-density lipoprotein induce IgG response in LDLR-/- mice and bind plasma autoantibodies in humans under enhanced carbamylation. Antioxid Redox Signal 2013, 19:1047-1062.
88. Alamanos Y., Drosos A.A. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005, 4:130-136.
89. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
90. Scott I.C., Steer S., Lewis C.M., Cope A.P. Precipitating and perpetuating factors of rheumatoid arthritis immunopathology: linking the triad of genetic predisposition, environmental risk factors and autoimmunity to disease pathogenesis. Best Pract Res Clin Rheumatol 2011, 25:447-468.
91. van Venrooij W.J., Zendman A.J.W., Pruijn G.J.M. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006, 6:37-41.
92. van der Woude D., Houwing-Duistermaat J.J., Toes R.E., Huizinga T.W., Thomson W., Worthington J., et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009, 60:916-923.
93. van der Helm-van Mil A.H., Verpoort K.N., Breedveld F.C., Toes R.E., Huizinga T.W. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R949-R958.
94. Nielen M.M., van der Horst A.R., van Schaardenburg D., van der Horst-Bruinsma I.E., van de Stadt R.J., Aarden L., et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005, 64:1199-1204.
95. Bos W.H., Wolbink G.J., Boers M., Tijhuis G.J., de Vries N., van der Horst-Bruinsma I.E., et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2010, 69:490-494.
96. Mjaavatten M.D., van der Heijde D., Uhlig T., Haugen A.J., Nygaard H., Sidenvall G., et al. The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis. Arthritis Res Ther 2010, 12:R76.
97. van der Woude D., Young A., Jayakumar K., Mertens B.J., Toes R.E., van der H.D., et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009, 60:2262-2271.
98. Nielen M.M., van Schaardenburg D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386.
99. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749.
100. Majka D.S., Deane K.D., Parrish L.A., Lazar A.A., Baron A.E., Walker C.W., et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 2008, 67:801-807.
101. Trouw L.A., Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 2012, 12:318-322.
102. Turunen S., Koivula M.K., Risteli L., Risteli J. Anticitrulline antibodies can be caused by homocitrulline-containing proteins in rabbits. Arthritis Rheum 2010, 62:3345-3352.
103. Shi J., Willemze A., Janssen G.M.C., van Veelen P.A., Drijfhout J.W., Cerami A., et al. Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the "AMC-Senshu" method. Ann Rheum Dis 2013, 72:148-150.
104. Shi J., van de Stadt L.A., Levarht E.W.N., Huizinga T.W.J., Toes R.E.M., Trouw L.A., et al. Anti carbamylated protein antibodies (anti-CarP) are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum 2013, 65:911-915.
105. Manners P.J., Bower C. Worldwide prevalence of juvenile arthritis - why does it vary so much?. J Rheumatol 2002, 29:1520-1530.
106. Hissink Muller P.C.E., Anink J., Shi J., Levarht E.W.N., Reinards T.H.C.M., Otten M.H., et al. Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. Ann Rheum Dis 2013, 72(12):2053-2055.
107. Senshu T., Sato T., Inoue T., Akiyama K., Asaga H. Detection of citrulline residues in deiminated proteins on polyvinylidene difluoride membrane. Anal Biochem 1992, 203:94-100.
108. Asaga H., Senshu T. Combined biochemical and immunocytochemical analyses of postmortem protein deimination in the rat spinal cord. Cell Biol Int 1993, 17:525-532.
109. Demoruelle M.K., Deane K. Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance. Curr Rheumatol Rep 2011, 13:421-430.